RESIDE
Financiado
Dissecting tissue resident lymphocyte homeostasis in humans
Natural killer (NK) cells contribute to tumor and antiviral immunity, regulate immune homeostasis, and impact on pregnancy success. These functions are in many instances performed in peripheral organs. Recent pioneering research i...
Natural killer (NK) cells contribute to tumor and antiviral immunity, regulate immune homeostasis, and impact on pregnancy success. These functions are in many instances performed in peripheral organs. Recent pioneering research in mouse models has revealed the existence and self-maintenance of tissue-resident (TR) NK cells. Although similar mechanisms are assumed to occur in humans, this has never been formally demonstrated and with our diverse infection history and active microbiota the human setting is considerably more complex. Me and my group have recently identified and characterized presumed TR NK cells in human liver and uterus. Here, we seek to challenge the prevailing concept from the mouse of how TR is formed, regulated, and maintained by taking advantage of world-unique surgical procedures for addressing lymphocyte tissue-residency, such as uterus transplantation and a novel liver surgery creating a human parabiosis situation, combined with single-cell technologies. In these settings, we will determine the detailed characteristics of subsets of NK cells permanently residing in tissues. With the different time windows as well as tissue sites presented by the clinical procedures, we will also assess kinetics of NK cell tissue repopulation. Furthermore, we aim to provide mechanistic insight into NK cell recirculation patterns by studying tissue-draining lymph fluid. Finally, we will study functional regulation of NK cell tissue-residency based on data from targeted single-cell RNAseq across multiple human tissues. The relevance of suspected and novel factors in regulating TR NK cells will be studied in a 3D microvasculature model combined with siRNA-based silencing of candidate genes. TR immune cells are poised to instantly deliver immune responses upon tumor and pathogen challenges while also being drivers of inflammation and autoimmunity in peripheral organs. Thus, this proposal has the potential to provide ground-breaking new knowledge in these areas.
ver más
Duración del proyecto: 61 meses
Fecha Inicio: 2020-12-02
Fecha Fin: 2026-01-31
Fecha Fin: 2026-01-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2020-12-02
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2020-STG:
ERC STARTING GRANTS
Cerrada
hace 5 años
Presupuesto
El presupuesto total del proyecto asciende a
1M€
Líder del proyecto
KAROLINSKA INSTITUTET
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
228.24K€ |
Participante